Sign up USA
Proactive Investors - Run By Investors For Investors

Bitcoin collapse continues; Wall Street stocks in historic loss

Trading at around US$6,360, the cryptocurrency has nearly halved in value in the past week alone
Bitcoin
The Bitcoin price collapse rumbles on

Such has been the collapse in Bitcoin price, many traders would have woken on Tuesday with long positions in the Dow Jones.

Monday saw New York’s headline index lose 1,175 points, equating to a 4.6% drop, marking the worst single trading session loss in Wall Street history.

READ: Collapsing Bitcoin price has taught new investors a painful lesson in trading

Bitcoin was down 8%, US$553 per coin at the time of writing. Trading at around US$6,360, the cryptocurrency has nearly halved in value in the past week alone and it has now shed almost 70% of its value since peaking above US$19,300 in mid-December.

Elsewhere, the value of other major digital currencies fell further. The price of Ethereum fell US$88 or 12.7% on Tuesday, changing hands at US$608 while the Ripple XRP token lost 17.5% to trade at 63.2 US cents.

Bitcoin and the cryptocurrencies are getting hit from all angles.

Broader volatility further threatens the virtual asset class, as many of the ‘establishment’ investors who helped buy the price up to peak levels are likely to be more inclined towards tangible stores of value.

The Bitcoin sell-off began with a spike in regulatory scrutiny, with pressure coming from watchdogs in several territories.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full INDU profile View Profile

US Market News Timeline

Newswire
March 15 2018

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use